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Abstract  
The resistance of kanamycin (KAN) as a second-line drug treatment for tuberculosis is associated with 
mutations in the 16S rRNA gene (rrsgene).rrsgene mutations occur at different locus causing changes in codons 
and amino acids.This study aimed to analyze mutations in the rrs gene and its relationship with the resistance of 
KANin isolate clinical sample ofMycobacterium tuberculosis(MTB). The isolate clinical sample of MTB was 
obtained from the TB HUM-RC laboratory. The analysis of rrs gene mutation was conducted using PCR 
sequencing. 
------------------------------------------------------------------------ 
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The results described that from 93 samples isolates, 51 (54.8%) samples shown multidrug resistant (MDR) 
while 42 samples shown (45.2%) non-MDR. Drug sensitivity test (DST) from the second line drugs samples 
isolates7 of 93 samples (7.5%) that shown resistance with KAN. The result of PCR sequencing shown6 (6.4%) 
of 93 isolates samples had mutations rrsgenein the locus of T1521C (1.1%), G1484C (1.1%), A1401G (2.1%), 
G940T (1.1%), and A514C (1.1%). Based on that gene locus, an unreported new mutation in the locus of rrs 
gene, called G940T,was discovered.The results of statistical analysis based on the number of mutations in each 
of anti-tuberculosis drugs indicate the p<0.05,described a relatioship between the mutation of rrs gene with the 
resistance of KAN. In conclusion, significance and impact of study, there is an association between the mutation 
in the rrs gene and the resistance to the second-line drugs of KAN in clinical isolates of MTB.Thus, samples of 
clinical isolates of MTB could be used to detect any resistance of KAN in advance. 
Keywords: Molecular; rrs Gene Mutation; Resistance of Kanamycin; Tuberculosis Patient. 
1. Introduction 
Tuberculosis is a major global health problem caused by Mycobacterium tuberculosis (MTB). In 2014, World 
Health Organization (WHO) estimated 9.6 million cases of tuberculosis worldwide and 1.5 million mortality 
from the disease.Referring to those numbers, 480.000 cases are predicted as the case ofmultidrug-resistant TB 
(MDR TB). One of the efforts initiated by WHO was the directly observed treatment short program (DOTS) 
(World Health Organization, 2015). Despite the progress in the area, there are still numerous cases which have 
not been discovered nor treated.The resistance against anti-tuberculosis medicine, especially multi-drug resistant 
TB (MDR-TB) and extensively-drug resistant TB (XDR-TB), considered as a serious threat in countering TB 
globally [1].  
The detection of drug-resistant TB is conducted by drug susceptibility testing (DST) either using media 
ofmycobacterium growth indicator tube (MGIT) orlowenstein-jensen (LJ). However, this procedure is 
constrained by the slow growth of MTBup to 2-4 weeks;thus requires longer construction.The rapid 
development of molecular medicine encourages the idea to identify mutationrelated to drug resistance that can 
reduce setback in diagnosisand proven to be more specific than the phenotype DST in several cases [1, 2] 
Basic understanding of the molecular resistance could help the discovery of a new methodtodetect the drug 
resistance towardsMTBstrain [3, 4,]. Spontaneous chromosomal mutation is a genetic basis for drug resistance 
in MTB.Various reports indicate the presence of anti-tuberculosis antibiotic resistancecaused by mutations in 
the mycobacteria gene (Engström and his colleagues 2012) [1]. Rifampicin resistance is associated with the 
changes in gene rpoB, while isoniazid resistance is associated with mutations in the gene of katG, inhA or aphC. 
Approximately, 80% of the strains become resistant to streptomycin due to mutations in the gene rpsL or 
rrs.Mutations in the gene of pncA is responsible for the resistance of pyrazinamide. Another mutation such as 
the gene of gyrA and B are used to detect the fluoroquinolones resistance such as ofloxacin, whilerrs gene is 
used to detect resistance against aminoglycoside class (KAN, AMK, CAP). However, methods used to detect 
resistance against KAN especially in Indonesia have not yet extensively studied. 
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KAN(2-deoxy aminoglycosides streptomycin) are classified as aminoglycoside class of antibiotics which have a 
broad spectrumand used as an alternative medicine for MDR-TB (Bauskenieks and his colleagues 2015). KAN 
of the main second-line drugs for tuberculosis treatment given to TB patientswhen MTBstrains are resistant to 
first-line anti-tuberculosis drugs, such asrifampicin, isoniazid, ethambutol, streptomycin or pyrazinamide.KAN 
works by binding 16S rRNA with the 30S ribosomal unitand inhibit protein synthesis of bacteria [1,3]. 
Nevertheless, the resistance of this drug againstMTBbecomes greater, ranging from 67.4–85.9% in KAN [4-6]. 
Mutations that generate resistance to aminoglycosides group have not been fully understood. KAN resistance 
has three mechanisms,the first mechanism is conducted by modifying aminoglycosides enzyme carried by 
transposons.The second mechanism is performed with the specific methylation of rRNA whereas the third 
mechanism involves changes of nucleotides in the 3'fromthe 16S rRNA gene [5]. Of these three mechanism, the 
most reported KAN resistance is the mutation of 16S rRNA gene (rrs) especially at nucleotide A1401G, 
C1402T, and G1484T from the clinical isolates [4-6]. 
Mutations number 1401 and 1484 are associated with resistance to all of the genes. Meanwhile,mutation at 
nucleotide 1484 is related with the resistance of capreomycin (CAP) and kanamicin (KAN). The most common 
mechanism of the resistance against KAN is mutation with the point from A to G at nucleotide 1400. In very 
rare cases, mutation founds from G to T in nucleotide 1483 at the 16S ribosomal rrs gene which leads to high 
levels of resistance to both drugs [4]. 
Based on preceding description, studies related to the rapid detection of molecular diagnostic techniquesis 
needed in order to determine the mutation in the rrs gene as a sign of KAN resistance. This research is important 
to understand how the detection of rrs gene in clinical isolatescould determine the diagnosis of the KAN 
resistance. The results of this study are expected to be applicable on identifying clinical isolates of MTBwith 
KAN resistant phenotype. 
2. Materials and Methods 
2.1 Research populations 
The study populations were pulmonary tuberculosis patients, suspected with MDR, examined in TB Hasanuddin 
University Medical Research Center (HUM-RC) laboratory on 2015. 
2.2 Research samples 
Samples of this research are MTBisolate clinical samples of MDR-suspected pulmonary tuberculosis 
patientswith the results of positive AFB examination and culture.Clinical isolates samples are collections stored 
at TB HUM-RC Laboratory.All samples had been passing through the stages of decontamination using a 
decontamination solution (NaOH 4% + Natrium citrate 2.9% + N-Acetyl L-Cysteine), smeared with Ziehl-
Neelsen, cultured in a liquid medium MGIT 960 (Mycobacteria Growth Indicator Tube) and finally identified 
using SD bioline.Thus, all clinical isolates samples used to detect resistance against KAN is positive culture of 
MTB. 
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2.3 Resistance test at medium MGIT 960 
The first stage in examining drug resistance is the preparation of medium MGIT 960.Stock concentrations of 
drugs being used are: streptomycin 83 µg/mL; isoniazid 8.3 µg/mL; rifampicin 83µg/mL, ethambutol 415 
µg/mL; kanamycin 210 µg/mL. Six tubes of MGIT 960 MGIT were labeled, including control.Each tube was 
added by 100 uL of antibioticsbased on the label of the tube.Then, 800 uL of oleic acid dexrose catalaseOADC 
were added into the MGIT tube.Finally, 500 µLof positive culture isolates were added into each tubeand 
incubated at37 °C for approximately 42 d. The reading was conducted using the BACTEC MGIT 960 Reader. 
2.4 Mutation analysis (polymorphisms)of rrs gene 
Mutations in the rrs gene as a sign of the antibiotic resistance against KANis detected using sequencing 
techniques.This technique consists of several stages such asDNA extraction, DNA amplification by polymerase 
chain reaction (PCR), electrophoresis agarose gel and sequencing method. 
2.5 Extraction of DNA from isolates ofMTB 
MTB DNA extraction was performed using sonication and boiling method. A total of 1 mL of clinical isolates 
from MGIT tube is put into a sterile 1.5 mL eppendorf tube.Then, it is centrifuged at a speed of 13000 rpm for 
15 min.Supernatant was removed and added with 100 µL of sterile water (ddH2O). Eppendorf tube containing 
isolates were then inserted into the water bath (at 95 °C) for 25 min. After that, itwas being sonicated for 20 min 
and centrifuged at 13000 rpm for 5 min.The DNA-containing supernatant was transferred to a new tube and 
stored at temperatures of -20°C (If it is not directly put into PCR).  
2.6 DNA amplification by PCR and electrophoresis 
The results of DNA extraction were inserted into the PCR Mix, such as 5 μL 5× buffer, 2 μL MgCl2, 1 μL dNTP 
mix, 1 μL Primerrrs forward F (5’–TAAACCTCTTTCACCATCGACG-3’), 1 μL primerrrs reverse 10 μM 
R(5’-CCTGGTAAGGTTCTTCGCGTTG-3’). It is also inserted into the 0.25 μL Hotstart taq enzyme (Qiagen), 
5 μL DNA template and nuclease free water, resulted into the total volume of 50μL for PCR.Amplification 
conditions consisted of 95 °C pre-denaturation for 5 min 1 cycle, denaturation 94 °C for 1 min, followed by 
annealing at 60 °C for 30 s, extension at 72 °C for 1 min, and being repeated for 40 cycles. The last cycle was 
the final extension at 72 °C for 10 min.The results of DNA amplification was continued using electrophoresis 
with 2% agarose gel contains ethidium bromide.Finally, electrophoresis results were observed under UV light. 
2.7 Sequencing Examination 
Mutational Analysis using direct sequencing method was performed at the 1st Base Laboratory of Malaysia.The 
PCR products was being sequenced to detect mutations in the rrs genewhich is then analyzed using software 
"Bioedit" and compared with data on "Gene Bank"in the NCBI database using methods of basic local alignment 
search tool (BLAST). 
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2.8 Data Analysis 
Data results of DNA sequencing in the form electrophenogram was aligned with normal sequences derived from 
GenBank, and then being analyzed using sequence alignment editor bioedit software version 7.0.5.1.Statistical 
analysis of the data was processed using SPSS version 21. 
3. Results  
Of the 93 samples examined by the first line anti-tuberculosis drug (FLD), 26 (28%) were found susceptible, 8 
(8.6%)were monoresistant to INH, 7 (7.5%) weremonoresistant to rifampicin, 1 (1.1%) shown to 
bepolyresistant, and 51(54.8%) were MDR, as described in Table 1.  
Table 1: Result of DST first line drug (FLD) andsecond line drug (SLD) Isolate 
Result ofFLD Result ofSLD 
DST n DST n 
  Suscept 26 Suscept 86 
Mono INH 8 Mono KAN 7 
Mono Rifampisin 7   
Polyresisten 1   
MDR 51   
Total  93 Total 93 
 
Furthermore, MDR Category was examined through its DST and rrs gene for the second-line-anti-tuberculosis 
(SLD) which isKAN. 
Following DSTexamination of KAN, we found 86 samples (92.4%) as susceptible, 7(7.5%) wasresistantagainst 
KAN, as shown in Table 2. 
Table 2: Relationship between mutation generrs with SLD resistance from clinicalMTB isolates 
Mutation ofrrs 
gene 
SLDResistance 
Total 
p Susceptible Resistance 
n % n % n % 
Non mutation 85 91.4 2 2.2 87 93.6 0.000 
Mutation 1 1.1 5 5.3 6 6.4 
Total  86 92.5 7 7.5 93 100.00 
(p<0.05)  
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Electrophoresis results of PCR products presented rrs gene amplification at 1200bp.Of the 93 isolate samples 
carried out rrs gene examination, 6 (6.4 %) observed mutation against KAN (Table 2). From the obtained 
results, 1 new mutation locus was discovered as G940T. The variation of mutational pattern on isolate samples 
towards KAN was depicted on Table 3. 
Tabel 3: Change of mutational patterns, codon and amino acid at KAN mutation 
Anti-
tuberculosis 
drugs 
Gene Mutational pattern Codon Amino acid 
Kanamycin rrs 514 A C AGC  CGC Serine arginine 
940 GT GCA  TCA Alanine  serine 
1401 A G TCA  TCG Serineserine 
1484 GC CGA  CCA Arginineproline 
1521 TC GCT  GCC Alanine alanine 
 
The results of statistical analysis based on the number of mutations in each of rrsgene shownthe p-value 
(p<0.05), proving the relationship between rrs gene mutations with KAN resistance in isolates (Table 2). 
4. Discussion 
Kanamycin is types of aminoglycoside. Aminoglycosides bind with ribosomes and disrupt the peptide chain 
elongation in bacteria.Mutation in the rrs gene with the code of 16S rRNA is associated with resistance against 
KAN.In the scope of microbiology, resistance is caused by genetic mutations, and it creates inefficacy in 
combating mycobacteria. Mutations occur spontaneously and produces resistance towards anti-tuberculosis 
drugs.Resistance to antimicrobials is the innate characteristic (inborn) of MTB. It is associated with a genetic 
mutation that occurs naturally in most populations ofMTBwild type. The emergence antimicrobial resistance is 
precipitated by the use of wrong antimicrobial andit is a man-made phenomenon. Resistance towards more than 
one antimicrobial drugs usually arises when the drugs are continuously consumed, increasing the numbers of 
drug-resistant MTB [7]. 
In this study, we obtained the smaller percentage ofrrs gene mutations againstKANthananother studies [1,3,8] . 
Study conducted by Campbell [2] showed thatof 314 isolate samples, 181 (57.6%) samplesare found to be 
resistantwith the second-linedrugs, and127 (40.4%) samples were mutated. 
In this study, the KAN-resistant mutated gene was found at the locus of T1521C, G1484C, A1401G, G940T and 
A514C. Whereas the research carried out by Jugheli(2009) showed that mutatedisolate samples on gene locus 
were found in locus A1401G and C1402T.Previous studies about locus mutations have been reported before 
[2,6,8], however, this study found a new locus mutation called G940T.Nucleotide changes in 1400, 1401 and 
1483 of the rrs gene have been particularly associated with resistance against KAN. The change of A → G in 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 31, No  1, pp 269-276 
275 
 
codon 1400 atrrs geneindicates resistanceagainst KAN from over 200 mg/mL MICs (Johnson and his colleagues 
2009). Indeed, resistance against KAN also occurs in nucleotide 1402 and 1484 [1]. 
According to thegene locus, mutationdue to resistanceagainst KANare located inT1521C,  G1484C, A1401G, 
G940T and A514C. In addition, study conducted by Jugheli [6] showed that mutational pattern in isolate 
sampelsare located in A1041G and C1402T. The similar mutational pattern also observed in another studies.  In 
this study, relationship between the rrs gene mutation and KAN resistance was found.With these results, the 
isolate clinical samples can be used to detect (genetic examination using PCR andsequencing) the occurence of 
KAN resistance in advance.  
This study described 1 sample mutation (T1521C) in the rrs gene examination but not resistant against KAN at 
the DST examination. This phenomenon occurred because mutation locus is considered as a nonsense mutation, 
in which there are no alteration in the amino acid (GTC/GCC= Alanine/Alanine). There is also two sample that 
shown resistance in the DST examination without any evidence of mutation. It is assumed that mutation 
occurred outside the locus target. Research carried out by Campbell [2] found that 54 of 181 sampels that 
resistant to anti-tuberculosis drugs shown no mutation. Molecular tests have several limitations, this test is 
incapable to include all types of mutations that occur in each resistance. Although some types of mutations that 
occur in every resistance has been widely known, some new mutations could occur and not necessarily 
associated with the pre-existing resistance. This phenomenon is the cause of resistance without accompanied 
with gene mutation [2, 10,11]. 
5. Conclusion  
In conclusion, significance and impact of study, there is an association between the mutation in the rrs gene and 
the resistance to the second-line drugs of KAN in clinical isolates of MTB.Thus, samples of clinical isolates of 
MTB could be used to detect any resistance of KAN in advance. 
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